CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
No fee travel rewards cards come with various features. Learn what to anticipate when using them for your travels.
14,338 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
SpaceX has landed a historic IPO. This article lays out a 180-day plan for investors, with key dates, valuations, and...
June brought a sharp turn for Newmont as gold dynamics and costs collided with production headwinds. This article bre...
A notable fund adds Masimo stock, signaling confidence in noninvasive monitoring tech. This analysis breaks down the ...
As Rocket Lab nears a pivotal earnings print, investors are quietly growing more bullish. This piece breaks down why ...
Magnite's 2025 earnings outlook centers on growing connected TV demand, platform efficiency, and navigating ad-tech p...
A potential shift at the Fed could ripple through stocks, bonds, and a retiree's paycheck. This in-depth look examine...
A fresh home price growth out—and signal is changing how buyers, homeowners, and lenders plan for 2026. This guide br...
The National Association of Realtors unveils a loan-focused podcast series designed to translate financing trends int...
Dallas-Fort Worth remains projected as the top housing market for a second year, signaling strong demand and rising h...
Mortgage-report fees are climbing again as Experian and other bureaus raise pricing. Industry sources say the latest ...
A new venue now enables 24/7 crypto trading, including weekends. Early weekend data shows growing interest and liquid...